HomeComparePSCBF vs JNJ

PSCBF vs JNJ: Dividend Comparison 2026

PSCBF yields 1818.18% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCBF wins by $4103414683.82M in total portfolio value
10 years
PSCBF
PSCBF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PSCBF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — PSCBF vs JNJ

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCBFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCBF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSCBF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, PSCBF beats the other by $3,147,377,270,442,242.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + JNJ for your $10,000?

PSCBF: 50%JNJ: 50%
100% JNJ50/50100% PSCBF
Portfolio after 10yr
$2051707341.93M
Annual income
$1,851,398,394,378,617.50/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PSCBF
No analyst data
Altman Z
-5.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys
0
JNJ buys
0
No recent congressional trades found for PSCBF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCBFJNJ
Forward yield1818.18%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$4103414683.84M$20.0K
Annual income after 10y$3,702,796,788,756,407.00$827.78
Total dividends collected$4074760433.31M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSCBF vs JNJ ($10,000, DRIP)

YearPSCBF PortfolioPSCBF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$192,518$181,818.18$10,676$355.77+$181.8KPSCBF
2$3,477,331$3,271,336.99$11,407$389.39+$3.47MPSCBF
3$58,943,217$55,222,471.89$12,198$426.53+$58.93MPSCBF
4$937,891,469$874,822,227.57$13,056$467.62+$937.88MPSCBF
5$14,012,869,532$13,009,325,660.38$13,987$513.12+$14012.86MPSCBF
6$196,647,994,247$181,654,223,846.76$14,998$563.56+$196647.98MPSCBF
7$2,592,865,386,485$2,382,452,032,641.56$16,098$619.52+$2592865.37MPSCBF
8$32,132,661,421,271$29,358,295,457,731.54$17,295$681.69+$32132661.40MPSCBF
9$374,409,247,740,494$340,027,300,019,734.44$18,599$750.82+$374409247.72MPSCBF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$20,022$827.78+$4103414683.82MPSCBF

PSCBF vs JNJ: Complete Analysis 2026

PSCBFStock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this PSCBF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHDPSCBF vs JEPIPSCBF vs OPSCBF vs KOPSCBF vs MAINPSCBF vs ABBVPSCBF vs MRKPSCBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.